UK markets open in 2 hours 10 minutes
NIKKEI 225
38,853.77 -46.25 (-0.12%) HANG SENG
18,934.74 +107.39 (+0.57%) CRUDE OIL
78.90 +1.18 (+1.52%) GOLD FUTURES
2,352.60 +18.10 (+0.78%) DOW
39,069.59 +4.29 (+0.01%) Bitcoin GBP
52,950.82 -874.29 (-1.62%)
AstraZeneca PLC (AZN.ST)
Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
At close: 05:29PM CEST
| Previous close | 1,672.50 |
| Open | 1,672.50 |
| Bid | 1,662.50 x 0 |
| Ask | 1,663.00 x 0 |
| Day's range | 1,659.00 - 1,674.00 |
| 52-week range | 1,261.00 - 1,697.00 |
| Volume | |
| Avg. volume | 265,761 |
| Market cap | 2.599T |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 38.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 30.74 (1.84%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Business Wire
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
CAMBRIDGE, England, May 27, 2024--Dato-DXd TL01 OS HLR
- Business Wire
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
WILMINGTON, Del., May 23, 2024--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.
- Business Wire
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
WILMINGTON, Del., May 22, 2024--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, 2024.
© 2024 Yahoo. All rights reserved.